Economic Analysis of Finasteride: A Model-Based Approach Using Data from the Proscar Long-Term Efficacy and Safety Study

June 1999 in “ Clinical Therapeutics ”

Peter C. Albertsen, James M. Pellissier, Franklin C. Lowe, Cynthia J. Girman, Claus G. Roehrborn

finasteride benign prostatic hyperplasia BPH Proscar

Studysummary In this study, finasteride was found to reduce costs associated with benign prostatic hyperplasia compared to watchful waiting and terazosin, especially in men with higher prostate-specific antigen levels.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

A study using data from the Proscar long-term efficacy and safety study found that finasteride is a cost-effective treatment for benign prostatic hyperplasia (BPH) compared to watchful waiting and terazosin over a 2-year period. Finasteride reduces the risk of acute urinary retention and surgery, resulting in cost savings. The study recommends finasteride as a viable option for BPH treatment.

View this study on clinicaltherapeutics.com →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

1054 citations , February 1998 in “The New England Journal of Medicine”

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.